You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Compatibility between Brain-Computer Interface and High-Efficiency Augmentative and Alternative Communication SystemsSBC: Prentke Romich Company Topic: NIDCD
Compatibility between Brain-Computer Interface and High Efficiency Augmentative and AlternativeCommunication Systems: Phase II ABSTRACT Brain-computer interfaces (BCI) enable text production for people who cannot move, but have only simple communication interfaces and are not widely used. Augmentative and alternative communication (AAC) systems are widely used and give efficient and precise commun ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic SyndromeSBC: Longeveron LLC Topic: NIA
The metabolic syndrome (MetS) is a cluster of factors that increases the risks for cardiovascular disease, type 2 diabetes mellitus, and mortality, and currently affects andgt; 40% of US adults. MetS is associated with endothelial dysfunction, decreased circulating endothelial progenitor cells (EPCs), and a pro-inflammatory state. We have made the exciting discovery that therapy with allogeneic me ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: GPB Scientific, Inc. Topic: 101
ABSTRACT The goal of this Fast-Track STTR project is to develop a Deterministic Lateral Displacement (DLD) microfluidic device that can enrich white blood cells (WBCs) from a typical leukapheresis unit in 1 hr, for use in manufacturing cancer cellular immunotherapy. Chimeric antigen receptor T cell (CAR-T) therapy has been recommended for FDA approval to treat relapsed or refractory pediatric and ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
Clinical validation and commercialization of a novel hydrogel-based vaginal packing system for pelvic brachytherapySBC: BrachyFoam, LLC Topic: 102
This proposal aims to complete preclinical validation and commercialize a novel vaginal packing product based upon a biocompatible polymer hydrogel strategy. The hydrogel will form in situ after being injected into a bag placed within the vaginal cavity during pelvic brachytherapy. The hydrogel packing can then be removed readily after the brachytherapy treatment. This Phase II proposal focuses on ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
Development of a Wearable Fluorescence Imaging Device for Intraoperative Identification of Brain TumorsSBC: BIOPTICS TECHNOLOGY LLC Topic: 102
ABSTRACTApproximatelypeople in the United States have been diagnosed with a primary brain tumorOf thesemalignant gliomasMGsaccount for approximatelyof all intracranial tumorswith an overall patient survival rate of onlyMore than any other cancerbrain cancer has lasting physicalcognitiveand psychological impacts on a patient s lifeand the highest per patient initial cost of careSurgical resection r ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Evolution of an Adaptable Prosthetic Foot Design for Normalization of Biomechanics During Community ParticipationSBC: OHIO WILLOW WOOD COMPANY, THE Topic: NICHD
Evolution of an Adaptable Prosthetic Foot Design for Normalization ofBiomechanics During Community Participation Summary/AbstractThe vision of this project is to improve the functional physical mobility of people with lower extremity amputations especially on uneven ground, side-slopes or when foot placement varies from side-to-side. People with amputations will be enabled to confidently participa ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: POINT DESIGNS, LLC Topic: NICHD
The Point DigitA Ratcheting Prosthetic Finger UsingAdvanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop and commercialize a purely mechanicalratcheting prosthetic fingerthe Point Digitwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s metacar ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: AUSCULTECH DX LLC Topic: NHLBI
PROJECT SUMMARY The overall goal of the proposed research and technology transfer effort is to develop a low-cost, point-of-care, mobile device-based technology for automated identification of Stillandapos;s murmur, the most common innocent (benign and harmless) heart murmur of childhood. This novel technology could reduce the current rate of over half a million children unnecessarily referred to ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Cetya Therapeutics, Inc. Topic: NHLBI
PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: BEAM Diagnostics, Inc. Topic: 41
PROJECT SUMMARY Fatal overdose from opioid misuse is one of the most pressing issues affecting the modern worldAs one of the nation s leading preventable causes of deatha critical line of defense against opioid use disorderOUDmust be standardized screening provided by the patient s primary care physicianpsychiatristand or counselorStandardized screening methods for opioidshoweverare simply inferio ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health